Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$507 Mln
Revenue (TTM)
$51 Mln
Net Profit (TTM)
$-21 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
6.8
Industry P/E
54.26
EV/EBITDA
0
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
16,420,900
CFO
$-54.28 Mln
EBITDA
$-25.26 Mln
Net Profit
$-55.56 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Itamar Medical - ADR
| -- | -- | -- | -- | -- | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2020
|
|---|---|
|
Itamar Medical - ADR
| 54.3 |
|
BSE Sensex
| 15.8 |
|
BSE Sensex
| 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Itamar Medical - ADR
|
0.0 | 506.9 | 50.9 | -21.2 | -37.8 | -26.5 | -- | 6.8 |
| 7.9 | 5,176.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 278.3 | 7,248.3 | 2,554.2 | 319.2 | 19.5 | 4.7 | 9.6 | 1.0 | |
| 36.8 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 112.8 | 6,098.9 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 8.9 | |
| 76.1 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.6 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 330.4 | 12,879.6 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.5 | 9.2 | |
| 117.8 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,409.8 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.1 | 2.6 |
Itamar Medical Ltd., a medical technology company, develops and commercializes non-invasive medical devices and solutions for the treatment of respiratory sleep disorders. The company offers medical devices based on Peripheral Arterial Tone (PAT)... signal, which measures changes in the patient's peripheral arterial pulse volumes and various parameters of arterial activities. It provides WatchPAT device, which enable to conduct home sleep apnea tests for the treatment of sleep apnea, such as obstructive sleep apnea; EndoPAT device that diagnoses endothelial dysfunction; and Loop device, a wrist device for measuring and recording physiological parameters, such as SpO2, respiration rate, and heart rate. The company operates in the United States, Canada, Europe, Israel, Japan, rest of the Asia Pacific, and internationally. The company was formerly known as Itamar Medical (CM) 1997 Ltd. and changed its name to Itamar Medical Ltd. in July 2000. Itamar Medical Ltd. was incorporated in 1997 and is headquartered in Caesarea, Israel. As of December 16, 2021, Itamar Medical Ltd. operates as a subsidiary of ZOLL Medical Corporation. Read more
Pres & CEO
Mr. Gilad Glick
Pres & CEO
Mr. Gilad Glick
Headquarters
Caesarea
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Itamar Medical Ltd - ADR is $0.00 (NASDAQ) as of 30-Dec-2021 EDT. Itamar Medical Ltd - ADR has given a return of --% in the last 1 years.
Since, TTM earnings of Itamar Medical Ltd - ADR is negative, P/E ratio is not available.
The P/B ratio of Itamar Medical Ltd - ADR is 6.84 times as on 30-Dec-2021, a 132 premium to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
|
2016
|
--
|
--
|
The 52-week high and low of Itamar Medical Ltd - ADR are Rs -- and Rs -- as of 04-Apr-2026.
Itamar Medical Ltd - ADR has a market capitalisation of $ 507 Mln as on 30-Dec-2021. As per SEBI classification, it is a company.
Before investing in Itamar Medical Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$--
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.